A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer

Journal of Medical Genetics

Volumn 43, Issue 11, 2006, Pages 863-866

  Cybulski, C ^a   Wokolorczyrk D ^a   Huzarski, T ^a   Byrski, T ^a   Gronwald, J ^a   Gorski B ^a   Debniak T ^a   Masojc B ^a   Jakubowska, A ^a   Gliniewicz, B ^a   Sikorski, A ^a   Stawicka, M ^b   Godlewski, D ^b   Kwias, Z ^c   Antczak, A ^c   Kraika, K ^d   Lauer, W ^d   Sosnowski, M ^e   Sikorska Radek, P ^f   Bar, K ^g   Klijer, R ^g   Zdrojowy, R ^g   Malkiewicz B ^g   Borkowski, A ^h   Borkowski, T ^h   Szwiec, M ⁱ   Narod, S A ^j   Lubinski J ^a   more..

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Center for Prevention and Epidemiology of Cancers OPEN   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f Clinic of Urology Regional Hospital   (Poland)

^g MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^h MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁱ Regional Oncology Hospital   (Poland)

^j Centre for Research on Women's Health   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; CONTROLLED STUDY; EXON; GENE DELETION; GENE MUTATION; GENETIC ASSOCIATION; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLAND; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER;

DNA MUTATIONAL ANALYSIS; EXONS; GENE DELETION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; GERM-LINE MUTATION; HUMANS; MALE; PEDIGREE; POLAND; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES;

EID: 33751202144     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2006.044974     Document Type: Article

References (21)

1. Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 2000;97:10389-94.
2. Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhou BB. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999;18:4047-54.
3. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DCR, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch J. Li FP, Garber JE, Haber DA. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999;286:2528-31.
4. Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001;61:5718-22.
5. CHEK2 Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31:55-9.
6. Oldenburg RA, Kroeze-Jansema K, Kraan J, Morreau H, Klijn JG, Hoogerbrugge N, Ligtenberg MJ, van Asperen CJ, Vasen HF, Meijers C, Meijers-Heijboer H, de Bock TH, Cornelisse CJ, Devilee P. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. Cancer Res 2003;63:8153-7.
7. Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H. A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet 2002;71:432-8.
8. CHEK2 Breast Cancer Case-Control Consortium. CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies, Am J Hum Genet 2004;74:1175-82.
9. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubinski J. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004;75:1131-5.
10. Kilpivaara O, Vahteristo P, Falck J, Syrjakoski K, Eerola H, Easton D, Bartkova J, Lukas J, Heikkila P, Aittomaki K, Holli K, Blomqvist C, Kallioniemi OP, Bartek J, Nevanlinna H. CHEK2 variant I157T may be associated with increased breast cancer risk. Int J Cancer 2004;111:543-7.
11. Shaag A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee MK, Ellis N, Offit K, Levy-Lahad E, King MC. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet 2005;14:555-63.
12. Cybulski C, Huzarski T, Gorski B, Masojc B, Mierzejewski M, Debniak T, Gliniewicz B, Matyjasik J, Zlowocka E, Kurzawski G, Sikorski A, Posmyk M, Szwiec M, Czajka R, Narod SA, Lubinski J. A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004;64:2677-9.
13. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 2003;72:270-80.
14. Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F, van den Bos R, de Snoo A, Fat GT, Brekelmans C, Jagmohan S, Franken P, Verkuijlen P, van den Ouweland A, Chapman P, Tops C, Moslein G, Burn J, Lynch H, Klijn J, Fodde R, Schutte M. The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet 2003;72:1308-14.
15. Allinen M, Huusko P, Mantyniemi S, Launonen V, Winqvist R. Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer 2001;85:209-12.
16. Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, Nathanson KL, Weber BL, Easton DF, Stratton MR, Rahman N. Breast Cancer Linkage Consortium. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet 2003;72:1023-8.
17. Bogdanova N, Enssen-Dubrowinskaja N, Feshchenko S, Lazjuk GI, Rogov YI, Dammann O, Bremer M, Karstens JH, Sohn C, Dork T. Association of two mutations in the CHEK2 gene with breast cancer. Int J Cancer 2005;116:263-6.
18. Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen MP, Tammela TL, Schleutker J. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 2003;89:1966-70.
19. Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H. CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet 2006;43:e34.
20. Rudd MF, Sellick GS, Webb EL, Catovskv D, Houlston RS. Variants in the ATM-BRCA2-CHEK2 axis predispose to cnronic lymphocytic leukaemia. Blood 2006;108:638-44.
21. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J, Roach KC, Mandell J, Lee MK, Ciernikova S, Foretova L, Soucek P, King MC. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295:1379-88.